الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 12 |  |  |
| | | from | 12 | | |
Abstract
SUMMARY AND UMMARY AND UMMARY AND CONCLUSION ONCLUSION ONCLUSION
he GBM is an incurable disease. The prognosis is very poor with few breakthroughs in management over the past decade. Patients without treatment usually survive for few months.
The aim of this study to evaluate efficacy and safety of adding TMZ to radiotherapy in GBM.
This study was conducted through revision of medical records of the patients who attended the Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University Hospital during the period from 2011 till 2013.
It is a retrospective study which included sixty patient with GBM in Ain Shams Hospitals to compare between two group:
Group I: thirty patients treated with adjuvant TMZ and radiotherapy concomitantly followed by TMZ. Patients age with range of 28-74years, with mean age of 53 years. Male to female ratio was 2:1, and ECOG scale was 90% in grade 0, 1.
Group II: thirty patients treated with adjuvant radiotherapy alone, Patients age with range of 34-65years, with mean age of 55 years. Male to female ratio was 1.5:1, and ECOG scale was 90% in grade 0,1.
In group I: the objective response were observed in 11 out of 30 patients with rate of 36.7%, disease stabilization was achieved in 12 patients with rate of 40%, progressed disease was observed in 7 patients with rate of 23.3%.
The median PFS was 7.1months, the 12 months PFS was 26.7%, the median OS was 14.2months, the 12months OS was 76.7%.
In group II: the objective response were observed in 6 out of 30 patients with rate of 20%, disease stabilization was achieved in 15patients with rate of 50%, progressed disease was observed in 9 patients with rate of 30%.
The median PFS was 5 months, the 12 months PFS was 10%, the median OS was 11.6months, the 12months OS was 40.2%.
TMZ was tolerated well by patients, with mild grade 3, 4 hematological toxicity in concomitant and adjuvant TMZ in compere with adjuvant radiotherapy.
Regarding of nonhematological toxicity was reported with mild to moderate grade 2, 3 toxicity in both group